JP2023537895A5 - - Google Patents
Info
- Publication number
- JP2023537895A5 JP2023537895A5 JP2023507508A JP2023507508A JP2023537895A5 JP 2023537895 A5 JP2023537895 A5 JP 2023537895A5 JP 2023507508 A JP2023507508 A JP 2023507508A JP 2023507508 A JP2023507508 A JP 2023507508A JP 2023537895 A5 JP2023537895 A5 JP 2023537895A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- fatty liver
- alcoholic fatty
- liver disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2020-0102604 | 2020-08-14 | ||
| KR20200102604 | 2020-08-14 | ||
| PCT/KR2021/010780 WO2022035271A1 (ko) | 2020-08-14 | 2021-08-13 | 삼중 활성체 지속형 결합체를 유효성분으로 포함하는 약학 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537895A JP2023537895A (ja) | 2023-09-06 |
| JP2023537895A5 true JP2023537895A5 (cg-RX-API-DMAC7.html) | 2024-08-20 |
Family
ID=80247218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507508A Pending JP2023537895A (ja) | 2020-08-14 | 2021-08-13 | 三重活性体持続型結合体を有効成分として含む薬学組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230302148A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4197560A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023537895A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220021890A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021324792A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3187742A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299800A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001599A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202220700A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022035271A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202301081B (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022035302A1 (ko) * | 2020-08-14 | 2022-02-17 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물 |
| KR20230004135A (ko) * | 2021-06-30 | 2023-01-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| RU2013133803A (ru) * | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
| KR102041412B1 (ko) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Fc 단편 유도체 |
| ES2602486T3 (es) * | 2012-06-21 | 2017-02-21 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran actividad de receptor de GIP |
| AU2014345570B2 (en) * | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| JP6712323B2 (ja) * | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体 |
| TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| WO2022035302A1 (ko) * | 2020-08-14 | 2022-02-17 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물 |
-
2021
- 2021-08-13 JP JP2023507508A patent/JP2023537895A/ja active Pending
- 2021-08-13 US US18/040,869 patent/US20230302148A1/en active Pending
- 2021-08-13 CA CA3187742A patent/CA3187742A1/en active Pending
- 2021-08-13 KR KR1020210107599A patent/KR20220021890A/ko active Pending
- 2021-08-13 WO PCT/KR2021/010780 patent/WO2022035271A1/ko not_active Ceased
- 2021-08-13 EP EP21856277.5A patent/EP4197560A4/en active Pending
- 2021-08-13 MX MX2023001599A patent/MX2023001599A/es unknown
- 2021-08-13 TW TW110129971A patent/TW202220700A/zh unknown
- 2021-08-13 AU AU2021324792A patent/AU2021324792A1/en active Pending
- 2021-08-13 IL IL299800A patent/IL299800A/en unknown
-
2023
- 2023-01-25 ZA ZA2023/01081A patent/ZA202301081B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10159714B2 (en) | Compositions, devices and methods of use thereof for the treatment of cancers | |
| JP4137184B2 (ja) | 薬物複合体の製造方法 | |
| JP2005523946A5 (cg-RX-API-DMAC7.html) | ||
| JP2024532619A5 (cg-RX-API-DMAC7.html) | ||
| US7291594B2 (en) | GLP-1 derivative and preparation thereof absorbable via mucous membrane | |
| JP2023518260A (ja) | アクチビン受容体ii型キメラ及びその使用方法 | |
| EP3212217A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| JP2017538395A5 (cg-RX-API-DMAC7.html) | ||
| BG64288B1 (bg) | 'ъ''ави на ов 'ля' про'...ин и м...'оди за 'яхно'о пол"-аван... | |
| JP2024540275A5 (cg-RX-API-DMAC7.html) | ||
| IL291681B2 (en) | Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease | |
| JP2023551877A5 (cg-RX-API-DMAC7.html) | ||
| JP2021514354A5 (cg-RX-API-DMAC7.html) | ||
| JP2023502005A5 (cg-RX-API-DMAC7.html) | ||
| JP2024544057A5 (cg-RX-API-DMAC7.html) | ||
| JP2024178193A (ja) | インスリン及びグルカゴンを含む薬学組成物 | |
| AU2024276534A1 (en) | Treatment of multiple sclerosis with anti-cd40l antibodies | |
| JP2009540842A5 (cg-RX-API-DMAC7.html) | ||
| JP2024527220A5 (cg-RX-API-DMAC7.html) | ||
| AU2024246525A1 (en) | Methods and uses for treating nausea and emesis | |
| JP2022513438A5 (cg-RX-API-DMAC7.html) | ||
| WO1999065512A1 (fr) | Compositions medicinales contenant des peptides apparentes au facteur de croissance des fibroblastes | |
| JP2024527220A (ja) | グルカゴン、glp-1及びgip受容体の全てに対して活性を有する三重活性体を含む組み合わせ物の治療学的用途 | |
| CN115531531A (zh) | 抗人vegf抗体和化疗联用在制备治疗结直肠癌药物中的用途 | |
| RU2025117117A (ru) | Фармацевтическая композиция для предупреждения или лечения заболевания "трансплантат против хозяина", содержащая производное GLP-2 или его конъюгат длительного действия |